tl;dr: Generic drug makers, with low profit margins, don't have a lot of excess capacity. Any disruption to supply can have a lasting effect, especially for complicated products like injectables.

Part of the fault is regulatory: Once that product is labelled for sale in country X, you can't sell excess inventory in country Y, even though it's the same product from the same production line.